Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16537985 | 0.90 | PDGFRB (0.48) | PDGFRBPDGFRA | |
| SCHEMBL16543583 | 0.89 | PDGFRB (0.48) | PDGFRBPDGFRA | |
| SCHEMBL16543581 | 0.89 | PDGFRB (0.48) | PDGFRBPDGFRA | |
| SCHEMBL18318734 | 0.87 | PDGFRB (0.51) | PDGFRBPDGFRA | |
| SCHEMBL16537585 | 0.86 | PDGFRB (0.49) | PDGFRBPDGFRA | |
| SCHEMBL16536881 | 0.86 | PDGFRB (0.49) | PDGFRBPDGFRA | |
| SCHEMBL16537787 | 0.86 | PDGFRB (0.48) | PDGFRBPDGFRA | |
| SCHEMBL18318550 | 0.86 | PDGFRB (0.52) | PDGFRBPDGFRA | |
| SCHEMBL18318661 | 0.86 | PDGFRB (0.49) | PDGFRBPDGFRA | |
| SCHEMBL3214568 | 0.86 | PDGFRB (0.52) | PDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113788824-A | Pyridine compound | 第一三共株式会社 | 2021-12-14 | — | — | CN | disclosed |
| CN-110036007-B | Pyridine compound | 第一三共株式会社 | 2021-10-15 | — | — | CN | disclosed |
| US-20210163464-A1 | PYRIDINE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-03 | — | — | US | disclosed |
| EP-3828178-A1 | PYRIDINE SALTS AND PROCESS | Daiichi Sankyo Company, Limited (JP) | 2021-06-02 | — | — | EP | disclosed |
| EP-3519398-B1 | PYRIDINE COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2021-02-24 | — | — | EP | disclosed |
| US-10851092-B2 | Pyridine compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-12-01 | — | — | US | disclosed |
| US-20200039974-A1 | PYRIDINE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-02-06 | — | — | US | disclosed |
| EP-3519398-A1 | PYRIDINE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-08-07 | — | — | EP | disclosed |
| WO-2018060714-A1 | PYRIDINE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-04-05 | — | — | WO | disclosed |
| US-9725465-B2 | Biaryl acetamide compounds and methods of use thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2017-08-08 | — | — | US | disclosed |
| WO-2011163610-A2 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2011-12-29 | — | — | WO | disclosed |
| WO-2011163610-A2 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2011-12-29 | — | — | WO | disclosed |
| US-RE36256-E | ADMINISTERING ARYL-SUBSTITUTED QUINOXALINE DERIVATIVES AS ANTIPROLIFERATIVE, ANTICARCINOGENIC AND ANTITUMOR AGENTS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| US-5795889-A | INHIBITING CELL GROWTH WITH ENZYME INHIBITORS FOR SKIN DISORDERS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-08-18 | — | — | US | disclosed |
| US-5656643-A | QUINOLIN PYRIDINE DERIVATIVES; USEFUL FOR TREATING CANCER, LEKEMIA, PSORIASIS, INFLAMMATORY DISODERS, BONE DISORDERS, ATHEROSCLEROSIS AND RESTENOSIS; CONTROLLS CELLULAR REPRODUCTION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-08-12 | — | — | US | disclosed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5409930-A | Inhibits abnoramal cell proliferation; dimethoxyquinoline/ dimethylquinoline/ quinolineoxide/ and quinoxaline derivatives | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-04-25 | — | — | US | disclosed |
| EP-0584222-A4 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE POULENC RORER INT (US) | 1994-07-06 | — | — | EP | disclosed |
| EP-0584222-A1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE. | RHONE POULENC RORER INT (US) | 1994-03-02 | — | — | EP | disclosed |
| WO-1992020642-A1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039974-A1 | PYRIDINE COMPOUND | RET, ROS1, ABL1 | PDGFRB 735/4885PDGFRA 632/4885 |
| US-20210163464-A1 | PYRIDINE COMPOUND | RET, ABL1, ROS1 | PDGFRB 763/4885PDGFRA 655/4885 |
| US-10851092-B2 | Pyridine compound | RET, ROS1, ABL1 | PDGFRB 735/4885PDGFRA 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.